FOXO4-DRI

FOXO4-DRI is a synthetic senolytic peptide that promotes apoptosis of senescent cells by disrupting the FOXO4-p53 interaction. It has demonstrated anti-aging potential by improving tissue function, reducing inflammation, and restoring youthful cellular profiles in preclinical aging models.

• Disrupts interaction between FOXO4 and p53, a protective axis in senescent cells
• Releases p53 from nuclear entrapment, leading to apoptosis in damaged senescent cells
• Promotes selective clearance of dysfunctional cells to restore tissue homeostasis
• Lowers SASP (senescence-associated secretory phenotype) inflammation markers

• unit: mg

  low dose: 1

  frequency: Once daily for 3–5 days per cycle

  high dose: 5

  standard dose: 2

  administration route: Subcutaneous (SQ)

• Typical protocol: 2–5 mg SubQ daily for 3–5 days. Repeat cycle every 3–6 months depending on aging status and tissue health markers.

warnings: ["Theoretical oncogenic risk — p53 pathway interference (theoretical)","Potential immune overload from rapid senescent cell clearance (theoretical)"]

sequence: DRI-modified FOXO4 sequence (D-retro-inverso analog)

half life: Not precisely defined; prolonged activity observed in preclinical studies

degradation: Metabolized by proteases; D-retro-inverso modifications enhance resistance

molecular weight: 1385.6

molecular formula: C63H100N18O19S2

tissue specificity: Targets senescent cells in aging tissues including muscle, fat, skin, and vasculature

• The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.mechanismPMID 40593617 ↗
• FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells.preclinicalPMID 31959736 ↗
• Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From Human Chondrocytes.preclinicalPMID 33996787 ↗